Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Umbilical cord blood transplantation may be able to replace
immune cells that were destroyed by the chemotherapy or radiation therapy that was used to
kill cancer cells.
PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation
plus combination chemotherapy in treating patients who have hematologic cancer or
nonmalignant hematologic disease.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)